Ketryx, the AI-native compliance platform for safety-critical product development, today announced record momentum following a year in which the company surpassed serving 100 million patients and proved that safety-critical product development no longer has to be slow. As medical device, digital health, diagnostics, and life sciences organizations accelerate from AI experimentation to enterprise-wide deployment, four of the top five Fortune 500 MedTech companies now run on Ketryx.
The company's platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles without disrupting workflows. Ketryx AI Agents cut manual work by 90 percent and close compliance gaps, elevating speed and quality across the entire product lifecycle. This comes as the industry faces increasing regulatory scrutiny and pressure to bring innovative products to market faster while maintaining safety.
To view the full announcement, including downloadable images, bios, and more, click here. Key takeaways from the announcement include Ketryx entering 2026 with record momentum as demand for validated AI surges, and four of the top five Fortune 500 MedTech companies now running on Ketryx, with the platform supporting products reaching more than 100 million patients worldwide.
Ketryx transforms the product lifecycle of life science teams to deliver safer products, faster. Trusted by four of the world’s top five medical device manufacturers, its AI-native compliance platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles—without disrupting existing workflows. Ketryx AI Agents cut manual work by 90 percent and close compliance gaps, elevating speed and quality across the entire product lifecycle. For more information, visit www.ketryx.com.
This announcement underscores the growing importance of validated AI in regulated industries. As medical device and life sciences companies expand their use of AI, platforms that ensure compliance and streamline development are becoming essential. Ketryx's adoption by major MedTech players signals a shift toward integrated, AI-native solutions that can handle the complexity of safety-critical product development while meeting regulatory requirements.
